Erwin Brenndörfer has joined LIDDS as Project Manager Translational Medicine and will be responsible for managing LIDDS growing portfolio of pre-clinical studies as well as continuing the development of the NanoZolid® technology and identifying new drugs that can be combined with NanoZolid®.
Erwin Brenndörfer has extensive experience in managing pre-clinical oncology studies gained during his time as a project leader for pre-clinical drug development at Medivir. Erwin will be working in the pre-clinial R&D team led by Martin Johansson.
Erwin has a PhD from Heinrich Heine University in Düsseldorf, Germany, and after completing his studies Erwin worked at Karolinska Institutet where he was an Assistant Professor of Infectious Diseases.
-We are very excited that Erwin has joined the LIDDS team. Our growing portfolio of pre-clinical projects means we also need to continue to grow and strengthen our organization. Erwin's experience and expertise are a great fit for LIDDS and he is a valuable addition to the LIDDS team, says Monica Wallter, CEO of LIDDS.
-LIDDS is an exciting company with a great team of people. I see a lot of potential in the NanoZolid® technology and I'm looking forward to using my skills and expertise to further develop LIDDS and the NanoZolid® technology, says Erwin Brenndörfer.
Erwin has been published more than 20 times in scientific publications, mainly on the Hepatitis C virus, and has been a frequent speaker at scientific conferences.
You can see an interview with Erwin at LIDDS LinkedIn page where he speaks about his role and what makes LIDDS and NanoZolid® so exciting: https://www.linkedin.com/company/lidds/
For additional information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 firstname.lastname@example.org
About LIDDS AB (publ)
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid® is clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit liddspharma.com
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire